CTKB vs. TXG, TRNS, EYPT, ALNT, LAB, AEHR, QSI, QTRX, SENS, and MASS
Should you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Cytek Biosciences vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
In the previous week, 10x Genomics had 9 more articles in the media than Cytek Biosciences. MarketBeat recorded 12 mentions for 10x Genomics and 3 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.91 beat 10x Genomics' score of 0.90 indicating that Cytek Biosciences is being referred to more favorably in the news media.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by insiders. Comparatively, 10.3% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.
Cytek Biosciences has a net margin of -5.71% compared to 10x Genomics' net margin of -25.14%. Cytek Biosciences' return on equity of -2.90% beat 10x Genomics' return on equity.
10x Genomics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
10x Genomics currently has a consensus target price of $14.96, suggesting a potential upside of 15.00%. Cytek Biosciences has a consensus target price of $5.60, suggesting a potential upside of 55.12%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than 10x Genomics.
Summary
10x Genomics and Cytek Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Cytek Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytek Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CTKB) was last updated on 7/2/2025 by MarketBeat.com Staff
